-
公开(公告)号：US20070128275A1
公开(公告)日：2007-06-07
申请号：US11519194
申请日：2006-09-11
申请人： Sonia Gervais , Damon Smith , Miloud Rahmouni , Pauline Contamin , Rachid Ouzerourou , My Ma , Angela Ferrada , Fouzia Soulhi
发明人： Sonia Gervais , Damon Smith , Miloud Rahmouni , Pauline Contamin , Rachid Ouzerourou , My Ma , Angela Ferrada , Fouzia Soulhi
IPC分类号： A61K9/22 , A61K31/496
CPC分类号： A61K9/2072 , A61K9/205 , A61K9/2054 , A61K9/2059 , A61K9/28 , A61K9/2866 , A61K31/135 , A61K31/16 , A61K31/167 , A61K31/4402 , A61K31/496
摘要： The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 hour to at least 24 hours after initial administration. After administration, the initial therapeutic action takes effect within the first hour and lasts at least about 24 hours. This therapeutic effect remains relatively and substantially stable for the remaining period of 24 hours. The formulations can be used for treating depression and/or sleeping disorders.
摘要翻译： 本发明涉及曲唑酮或曲唑酮衍生物每天一次的制剂。 制剂含有曲唑酮或曲唑酮衍生物和控制释放赋形剂，使得一旦口服给药，曲唑酮或曲唑酮衍生物在治疗血浆浓度后维持在初次给药后至少1小时至至少24小时。 给药后，初始治疗作用在第一小时内生效，持续至少约24小时。 这种治疗效果在24小时的剩余时间内保持相对且基本稳定。 制剂可用于治疗抑郁症和/或睡眠障碍。
-
公开(公告)号：US09439866B2
公开(公告)日：2016-09-13
申请号：US12892454
申请日：2010-09-28
申请人： Sonia Gervais , Damon Smith , Miloud Rahmouni , Pauline Contamin , Rachid Ouzerourou , My Linh Ma , Angela Ferrada , Fouzia Soulhi
发明人： Sonia Gervais , Damon Smith , Miloud Rahmouni , Pauline Contamin , Rachid Ouzerourou , My Linh Ma , Angela Ferrada , Fouzia Soulhi
IPC分类号： A61K9/20 , A61K9/28 , A61K31/16 , A61K31/496 , A61K31/135 , A61K31/167 , A61K31/4402
CPC分类号： A61K9/2072 , A61K9/205 , A61K9/2054 , A61K9/2059 , A61K9/28 , A61K9/2866 , A61K31/135 , A61K31/16 , A61K31/167 , A61K31/4402 , A61K31/496
摘要： The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 hour to at least 24 hours after initial administration. After administration, the initial therapeutic action takes effect within the first hour and lasts at least about 24 hours. This therapeutic effect remains relatively and substantially stable for the remaining period of 24 hours. The formulations can be used for treating depression and/or sleeping disorders.
摘要翻译： 本发明涉及曲唑酮或曲唑酮衍生物每天一次的制剂。 制剂含有曲唑酮或曲唑酮衍生物和控制释放赋形剂，使得一旦口服给药，曲唑酮或曲唑酮衍生物在治疗血浆浓度后维持在初次给药后至少1小时至至少24小时。 给药后，初始治疗作用在第一小时内生效，持续至少约24小时。 这种治疗效果在24小时的剩余时间内保持相对且基本稳定。 制剂可用于治疗抑郁症和/或睡眠障碍。
-
公开(公告)号：US07829120B2
公开(公告)日：2010-11-09
申请号：US11519194
申请日：2006-09-11
申请人： Sonia Gervais , Damon Smith , Miloud Rahmouni , Pauline Contamin , Rachid Ouzerourou , My Linh Ma , Angela Ferrada , Fouzia Soulhi
发明人： Sonia Gervais , Damon Smith , Miloud Rahmouni , Pauline Contamin , Rachid Ouzerourou , My Linh Ma , Angela Ferrada , Fouzia Soulhi
CPC分类号： A61K9/2072 , A61K9/205 , A61K9/2054 , A61K9/2059 , A61K9/28 , A61K9/2866 , A61K31/135 , A61K31/16 , A61K31/167 , A61K31/4402 , A61K31/496
摘要： The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 hour to at least 24 hours after initial administration. After administration, the initial therapeutic action takes effect within the first hour and lasts at least about 24 hours. This therapeutic effect remains relatively and substantially stable for the remaining period of 24 hours. The formulations can be used for treating depression and/or sleeping disorders.
摘要翻译： 本发明涉及曲唑酮或曲唑酮衍生物每天一次的制剂。 制剂含有曲唑酮或曲唑酮衍生物和控制释放赋形剂，使得一旦口服给药，曲唑酮或曲唑酮衍生物在治疗血浆浓度后维持在初次给药后至少1小时至至少24小时。 给药后，初始治疗作用在第一小时内生效，持续至少约24小时。 这种治疗效果在24小时的剩余时间内保持相对且基本稳定。 制剂可用于治疗抑郁症和/或睡眠障碍。
-
公开(公告)号：US20090175937A1
公开(公告)日：2009-07-09
申请号：US12336495
申请日：2008-12-16
申请人： Miloud Rahmouni , Angela Ferrada , Fouzia Soulhi , Sonia Gervais , Vinayak Sant , Damon Smith , Frederic Duffayet , Shams Rustom , Ali El-Jammal , Jean-Michel Ndong , Bobby-Ernst Boursiquot , Ali Bichara
发明人： Miloud Rahmouni , Angela Ferrada , Fouzia Soulhi , Sonia Gervais , Vinayak Sant , Damon Smith , Frederic Duffayet , Shams Rustom , Ali El-Jammal , Jean-Michel Ndong , Bobby-Ernst Boursiquot , Ali Bichara
CPC分类号： A61K9/2081 , A61K9/14 , A61K9/20 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2031 , A61K9/205 , A61K9/2054 , A61K9/2077 , A61K9/209 , A61K9/28 , A61K9/2813 , A61K9/282 , A61K9/284 , A61K9/2846 , A61K9/286 , A61K9/2866 , A61K9/50 , A61K31/00 , A61K31/135 , A61K31/137 , A61K31/167 , A61K31/485
摘要： Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the core, and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core, the coat, or both the core and the coat. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the core swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the formulation. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof.
摘要翻译： 公开了一种滥用预防性控制释放制剂，其包含包含超吸收材料（例如，聚卡波非）的核心，围绕该核心的控释包衣以及具有药物活性剂（例如，阿片样物质止痛剂）的多个控制释放微粒 ）设置在芯部，外壳中，或芯部和外壳两者之间。 当被故意地或意外地粉碎并暴露于含水介质时，存在于芯中的超吸收材料溶胀以包封微粒，其保持基本上完整，从而延缓药物活性剂从制剂中的释放。 还公开了使用滥用预防性控制释放制剂将药学活性剂递送至有需要的哺乳动物例如人的方法。
-
公开(公告)号：US08486448B2
公开(公告)日：2013-07-16
申请号：US12336495
申请日：2008-12-16
申请人： Miloud Rahmouni , Angela Ferrada , Fouzia Soulhi , Sonia Gervais , Vinayak Sant , Damon Smith , Frederic Duffayet , Shams Rustom , Ali El-Jammal , Jean-Michel Ndong , Bobby-Ernst Boursiquot , Ali Bichara
发明人： Miloud Rahmouni , Angela Ferrada , Fouzia Soulhi , Sonia Gervais , Vinayak Sant , Damon Smith , Frederic Duffayet , Shams Rustom , Ali El-Jammal , Jean-Michel Ndong , Bobby-Ernst Boursiquot , Ali Bichara
IPC分类号： A61K9/20
CPC分类号： A61K9/2081 , A61K9/14 , A61K9/20 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2031 , A61K9/205 , A61K9/2054 , A61K9/2077 , A61K9/209 , A61K9/28 , A61K9/2813 , A61K9/282 , A61K9/284 , A61K9/2846 , A61K9/286 , A61K9/2866 , A61K9/50 , A61K31/00 , A61K31/135 , A61K31/137 , A61K31/167 , A61K31/485
摘要： Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the core, and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core, the coat, or both the core and the coat. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the core swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the formulation. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof.
摘要翻译： 公开了一种滥用预防性控制释放制剂，其包含包含超吸收材料（例如，聚卡波非）的核心，围绕该核心的控释包衣以及具有药物活性剂（例如，阿片样物质止痛剂）的多个控制释放微粒 ）设置在芯部，外壳中，或芯部和外壳两者之间。 当被故意地或意外地粉碎并暴露于含水介质时，存在于芯中的超吸收材料溶胀以包封微粒，其保持基本上完整，从而延缓药物活性剂从制剂中的释放。 还公开了使用滥用预防性控制释放制剂将药学活性剂递送至有需要的哺乳动物例如人的方法。
-
公开(公告)号：US20110021535A1
公开(公告)日：2011-01-27
申请号：US12892454
申请日：2010-09-28
申请人： Sonia Gervais , Damon Smith , Miloud Rahmouni , Pauline Contamin , Rachid Ouzerourou , My Linh Ma , Angela Ferrada , Fouzia Soulhi
发明人： Sonia Gervais , Damon Smith , Miloud Rahmouni , Pauline Contamin , Rachid Ouzerourou , My Linh Ma , Angela Ferrada , Fouzia Soulhi
IPC分类号： A61K31/496 , A61P25/20 , A61P25/24
CPC分类号： A61K9/2072 , A61K9/205 , A61K9/2054 , A61K9/2059 , A61K9/28 , A61K9/2866 , A61K31/135 , A61K31/16 , A61K31/167 , A61K31/4402 , A61K31/496
摘要： The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 hour to at least 24 hours after initial administration. After administration, the initial therapeutic action takes effect within the first hour and lasts at least about 24 hours. This therapeutic effect remains relatively and substantially stable for the remaining period of 24 hours. The formulations can be used for treating depression and/or sleeping disorders.
摘要翻译： 本发明涉及曲唑酮或曲唑酮衍生物每天一次的制剂。 制剂含有曲唑酮或曲唑酮衍生物和控制释放赋形剂，使得一旦口服给药，曲唑酮或曲唑酮衍生物在治疗血浆浓度后维持在初次给药后至少1小时至至少24小时。 给药后，初始治疗作用在第一小时内生效，持续至少约24小时。 这种治疗效果在24小时的剩余时间内保持相对且基本稳定。 制剂可用于治疗抑郁症和/或睡眠障碍。
-
公开(公告)号：US20110015205A1
公开(公告)日：2011-01-20
申请号：US12892466
申请日：2010-09-28
申请人： Sonia Gervais , Damon Smith , Miloud Rahmouni , Pauline Contamin , Rachid Ouzerourou , My Linh Ma , Angela Ferrada , Fouzia Soulhi
发明人： Sonia Gervais , Damon Smith , Miloud Rahmouni , Pauline Contamin , Rachid Ouzerourou , My Linh Ma , Angela Ferrada , Fouzia Soulhi
IPC分类号： A61K31/496 , A61P25/24
CPC分类号： A61K9/2072 , A61K9/205 , A61K9/2054 , A61K9/2059 , A61K9/28 , A61K9/2866 , A61K31/135 , A61K31/16 , A61K31/167 , A61K31/4402 , A61K31/496
摘要： The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 hour to at least 24 hours after initial administration. After administration, the initial therapeutic action takes effect within the first hour and lasts at least about 24 hours. This therapeutic effect remains relatively and substantially stable for the remaining period of 24 hours. The formulations can be used for treating depression and/or sleeping disorders.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.014 秒)
